Patents by Inventor Yong-sung Kim

Yong-sung Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220190347
    Abstract: An embodiment anode for an all-solid-state battery includes an anode current collector, and a coating layer disposed on the anode current collector, wherein the coating layer is a thin film including at least one metal selected from the group consisting of alkaline earth metals, Group 4 to 9 transition metals, Group 13 metals, or combinations thereof.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Inventors: Yong Gu Kim, Yun Sung Kim, Sa Heum Kim, Hong Seok Min
  • Publication number: 20220166008
    Abstract: An embodiment anode active material for an all-solid-state battery includes a carbon-based material including carbon-based particles and a coating layer formed on a surface of the carbon-based particles, the coating layer comprising amorphous carbon, and a silicon-based material. An embodiment method of manufacturing an anode active material for an all-solid-state battery includes manufacturing a carbon-based material by forming a coating layer including amorphous carbon from a hydrocarbon gas on a surface of carbon-based particles through thermal chemical vapor deposition, manufacturing a silicon-based material through thermal chemical vapor deposition using a feed comprising silane gas and ammonia gas, and mixing the carbon-based material and the silicon-based material.
    Type: Application
    Filed: October 28, 2021
    Publication date: May 26, 2022
    Inventors: Sung Woo Noh, Ju Yeong Seong, Yong Gu Kim, In Woo Song, Hong Seok Min, Yong Sub Yoon, Yun Sung Kim, A Reum Ha, Yong Jun Jang, Sang Heon Lee, Ki Hong Ahn, Jae Phil Cho
  • Publication number: 20220162342
    Abstract: Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.
    Type: Application
    Filed: November 3, 2021
    Publication date: May 26, 2022
    Inventors: Yong Sung Kim, Hye Ji Choi, Eun Sil Sung
  • Publication number: 20220155974
    Abstract: Disclosed herein is a device equipped with flash memory, which includes memory in which at least one program is recorded and a processor for executing the program. The memory includes flash memory including a data area and a backup area, and the program divides data into two or more segments depending on whether the data can be stored in a single page and stores the same in the data area. The first segment is stored in a page along with a segment number, indicating the sequential position of the divided data, a segment offset, indicating the number of pages between the pages in which the current segment and the next segment are stored, the size of a data file name, the size of the data, and the file name. At least one additional segment may be stored in another page along with the segment number and segment offset thereof.
    Type: Application
    Filed: October 21, 2021
    Publication date: May 19, 2022
    Inventors: Yong-Sung JEON, Doo-Ho CHOI, Ha-Young SEONG, Mi-Kyung OH, Sang-Jae LEE, Ik-Kyun KIM
  • Patent number: 11336444
    Abstract: Disclosed herein are a hardware security module, a device having the hardware security module, and a method for operating the device. The method for verifying integrity of executable code in a device includes dividing, by a Micro-Control Unit (MCU), executable code into multiple blocks, generating, by the MCU, hash values corresponding to the blocks resulting from the division, storing, by a Hardware Security Module (HSM), the generated hash values, calculating, by the MCU, at least one hash value, among hash values of the multiple blocks when the executable code boots, and comparing, by the HSM, the calculated hash value with a hash value corresponding to the calculated hash value, among the hash values stored in the HSM.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: May 17, 2022
    Assignee: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Yong-Sung Jeon, You-Sung Kang, Byoung-Koo Kim, Sang-Jae Lee, Seung-Kwang Lee, Doo-Ho Choi
  • Publication number: 20220150911
    Abstract: The disclosure relates to a 5G or 6G communication system for supporting a higher data transmission rate than a 4G communication system such as LTE. The disclosure relates to a method and an apparatus for enhancement of self-interference channel estimation performance to secure self-interference removal performance in full-duplex (FD) communication and, more specifically, to a method and an apparatus for scheduling a transmission resource for enhanced self-interference channel estimation in the FD communication.
    Type: Application
    Filed: November 11, 2021
    Publication date: May 12, 2022
    Inventors: Kwonjong LEE, Sang-Hyo KIM, Hyojin LEE, Min Young CHUNG, Dong Hyun KONG, Yong-Sung KIL, Seungil PARK, Seunghyun LEE
  • Patent number: 11291722
    Abstract: The present invention relates to a vaccine composition comprising cyclic peptides of the present invention, antibodies to cyclic peptides, or an anticancer composition comprising them, and the vaccine composition of the present invention exhibit an inhibitory activity for metastasis of cancer. In addition, the antibodies of the present invention bind to the tumor-specific antigen TM4SF5 with high affinity, and significantly inhibit the growth, metastasis and invasion of cancer cells expressing the tumor-specific antigen TM4SF5, and thus can be used for diagnosis, prevention or treatment of various cancers expressing TM4SF5.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 5, 2022
    Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIVERSITY
    Inventors: Hyung Joo Kwon, Yong Sung Kim
  • Patent number: 11286311
    Abstract: Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 29, 2022
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung Kim, Hye Ji Choi, Eun Sil Sung
  • Publication number: 20220041683
    Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 10, 2022
    Inventors: Yong Sung KIM, Ye Jin KIM
  • Publication number: 20210403580
    Abstract: An antibody or antigen-binding fragment thereof, which binds with a high pM-level affinity to a human IL-4 receptor alpha chain that is a human IL-4 receptor, is provided. The antibody or antigen-binding fragment has a different epitope and a different antigen dissociation rate than existing antibodies. A nucleic acid encoding the antibody or antigen-binding fragment thereof, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or antigen-binding fragment thereof, a conjugate comprising the antibody or antigen-binding fragment thereof, a composition for preventing or treating inflammatory diseases, and a composition for diagnosing inflammatory diseases are disclosed.
    Type: Application
    Filed: November 7, 2019
    Publication date: December 30, 2021
    Applicant: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung KIM, Hae-Sim PARK, Jung Eun KIM, Keunok JUNG
  • Patent number: 11155641
    Abstract: The present disclosure relates to a cytosol-penetrating antibody and the use thereof, and more specifically to identification of a structural mechanism that induces escape from endosomes into the cytosol after cellular internalization into living cells through a cell membrane protein, a light-chain variable region and/or heavy-chain variable region, which is based on this identification and has a significantly improved ability to escape from endosomes into the cytosol, a cytosol-penetrating antibody comprising the same, a method for producing the same, and the use thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: October 26, 2021
    Assignee: ORUM THERAPEUTICS INC.
    Inventors: Yong Sung Kim, Ji Sun Kim, Jae Yeong Park
  • Patent number: 11155639
    Abstract: A method for evaluating and screening a mutant inducing the high-efficiency formation of heterodimers from a human antibody heavy chain constant region mutant pair combination library in order to increase the yield of formation of human antibody heterodimeric heavy chain constant regions. A heterodimeric heavy chain constant region (heterodimeric F) library is obtained by the method. A CH3 domain mutant pair, in which the formation of the heterodimeric heavy chain constant regions is preferred in the library, forms heterodimeric heavy chain constant regions at a high yield of at least 80-90%, and also has excellent thermal stability and retains binding ability to the heavy chain constant region receptor (FcRn).
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: October 26, 2021
    Assignee: AJOU UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Sung Kim, Hye Ji Choi, Ji Hee Ha
  • Publication number: 20210253657
    Abstract: A composition comprises, as an active ingredient, a fusion protein obtained by fusion of a tumor-penetrating peptide and an anti-angiogenic agent. The tumor-penetrating peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5 to SEQ ID NO: 7.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 19, 2021
    Inventors: Hyuk-Sang Kwon, Jong-Hee Ko, Young-Min Lee, Hyei-Yoon Jung, Seok-Woo Yang, Jae-Hoon Kang, Yong-Sung Kim
  • Patent number: 11078249
    Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: August 3, 2021
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Sung Kim, Keunok Jung, Ji Hee Ha, Dong Ki Choi, Hye Ji Choi, Ye Jin Kim
  • Publication number: 20210220436
    Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 22, 2021
    Inventors: Seong Beom KIM, Hyei Yoon JUNG, Seok Woo YANG, Hyuk Sang KWON, Jae-Hoon KANG, Yong-Sung KIM
  • Patent number: 11059283
    Abstract: Provided is a screen printing device. A screen printing device according to an embodiment of the present invention includes: a screen disposed adjacent to an upper portion of a substrate on which a printing process is performed, and having a pattern to be printed on the substrate; a printing unit disposed on an upper portion of the screen and configured to discharge ink supplied from the outside to the screen and to print the pattern on the substrate; a driver connected to at least one of the screen and the printing unit and configured to drive at least one of the screen and the printing unit; and a controller connected to the printing unit and the driver and configured to control operations of the printing unit and the driver, wherein, when at least one of the screen and the printing device moves in a state in which the printing unit contacts the screen, the controller controls the printing device to perform printing on the substrate by using discharge pressure of the ink.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: July 13, 2021
    Assignee: SUNG AN MACHINERY CO., LTD
    Inventors: Yong Sung Kim, Jin Woo Seong
  • Patent number: 11052130
    Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 6, 2021
    Assignee: ILDONG PHARM CO., LTD.
    Inventors: Seong Beom Kim, Hyei Yoon Jung, Seok Woo Yang, Hyuk Sang Kwon, Jae-Hoon Kang, Yong-Sung Kim
  • Publication number: 20210198340
    Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.
    Type: Application
    Filed: March 8, 2021
    Publication date: July 1, 2021
    Inventors: Yong Sung Kim, Ye Jin Kim
  • Patent number: 10919947
    Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 16, 2021
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Hyuk-Sang Kwon, Jong-Hee Ko, Young-Min Lee, Hyei-Yoon Jung, Seok-Woo Yang, Jae-Hoon Kang, Yong-Sung Kim
  • Patent number: 10903005
    Abstract: A composite electronic component includes a capacitor including a capacitor body including a dielectric layer and first and second internal electrodes alternately stacked with the dielectric layer interposed therebetween, and first and second electrodes disposed on the capacitor body, and a varistor including a varistor body including ZnO and third and fourth electrodes disposed on the varistor body, wherein the first electrode is electrically connected to the third electrode and the second electrode is electrically connected to the fourth electrode.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: January 26, 2021
    Assignee: SAMSUNG ELECTRO-MECHANICS CO., LTD.
    Inventors: Hae In Kim, Eun Ju Oh, Yong Sung Kim